E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Reversal of vitamin K antagonist (VKA) induced anticoagulation in patients needing urgent surgery associated with significant bleeding risk. |
|
E.1.1.1 | Medical condition in easily understood language |
Reversal of vitamin K antagonist (VKA) induced anticoagulation in patients needing urgent surgery associated with significant bleeding risk. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10065667 |
E.1.2 | Term | Haemorrhage prophylaxis |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to demonstrate that the efficacy of OCTAPLEX as a reversal agent in patients under VKA therapy with the need for urgent surgery with significant bleeding risk is clinically non-inferior to Beriplex® P/N (Kcentra). |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective of the study is to investigate the safety and tolerability of OCTAPLEX compared to Beriplex® P/N (Kcentra) in patients under VKA therapy with the need for urgent surgery with significant bleeding risk. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female patients at least 18 years of age. 2. Patients currently on oral anticoagulation treatment with VKA of coumadin or warfarin type. 3. Patients being admitted to the hospital or currently hospitalized where: • an urgent surgery carrying significant bleeding risk (≥50 mL expected blood loss) is required as part of routine clinical care; • the use of oral or parenteral vitamin K alone to reverse anticoagulation is deemed too slow or inappropriate for reversal; 4. Patients with an INR of 2.0 or above at the time of decision to reverse the anticoagulation status. 5. Patients who have given written informed consent and who are able and willing to comply with the procedures laid out in the study protocol.
|
|
E.4 | Principal exclusion criteria |
1. Patients with a life expectancy of less than 48 hours per physician’s judgment (e.g., patients with a Glasgow Coma Scale equal to 3 or a head Abbreviated Injury Score of 6, patients requiring continuous inotropic or pressor support, and patients whose status is post cardiac arrest). 2. Patients for whom the planned surgery or procedure is commonly associated with a very low bleeding risk (e.g., catheter placement, gastroscopy). 3. Patients with a history of TEEs, myocardial infarction (MI), unstable angina pectoris, critical aortic stenosis, cerebrovascular accident, TIA, severe peripheral vascular disease, or disseminated intravascular coagulation within 3 months of enrollment. 4. Patients with a known congenital bleeding disorder. 5. Patients with a known antiphospholipid antibody syndrome. 6. Patients with present or past specific factor inhibitor activity. 7. Patients with thrombocytopenia of <80,000/μL or history of heparin-induced thrombocytopenia. 8. Patients who have received heparin of any type or any non-VKA anticoagulant within 24 hours prior to enrollment into the study or with potential need to receive these medications before completion of hemostasis evaluation at the end of surgery. 9. Patients who have received PCCs, FFP or vitamin K within 72 hours prior to enrollment into the study. 10. Patients with a known history of hypersensitivity to plasma-derived products. 11. Patients with acute major bleeding or polytrauma. 12. Pregnant or nursing women. 13. Patients participating in another interventional clinical study currently or during the past 30 day prior to enrollment into this study. 14. Patients previously enrolled in this study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the hemostatic efficacy rating at the end of the surgery. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Proportion of patients with an INR value of less than or equal to 1.5 at 30 min (± 15 min) after the end of infusion. • Change in coagulation factor levels from baseline to 30 (± 15 min) after the end of infusion: o Factor FII o Factor FVII o Factor FIX o Factor FX • Proportion of patients receiving red blood cells (RBC) during the surgery
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• Proportion of patients with an INR value of less than or equal to 1.5 at 30 min (± 15 min) after the end of infusion. • Change in coagulation factor levels from baseline to 30 (± 15 min) after the end of infusion: o Factor FII o Factor FVII o Factor FIX o Factor FX • Proportion of patients receiving red blood cells (RBC) during the surgery
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 29 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
United States |
Poland |
Bulgaria |
Romania |
Spain |
Germany |
Russian Federation |
Ukraine |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |